Shares of other companies:
April 29, 2024 Tesla, Baidu Join Forces for Self-Driving Tech in China
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Facing A Liquidity Crunch; Dilution Ahead?
April 29, 2024
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
KRYS Stock News and Mentions of Krystal Biotech, Inc. Stocktwits
Updated: April 30, 2024 (10:17)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Krystal Biotech Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Krystal Biotech, Inc. (KRYS).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Krystal Biotech stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Krystal Biotech, Inc. (KRYS)
April 26, 2024 (11:00) / "Benzinga" (by Globe Newswire)
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024 - Krystal Biotech ( NASDAQ:KRYS )
PITTSBURGH, April 26, 2024 ( GLOBE NEWSWIRE ) -- Krystal Biotech, Inc. ( the "Company" ) KRYS, a commercial-stage biotechnology company, today announced that it will report its first quarter 2024 financial results on Monday, May 6, 2024, prior to the open of U.S. markets.
In Article Trend: Somewhat-Bullish
April 26, 2024 (11:00) / "GlobeNewswire" (by Inc.)
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
PITTSBURGH, April 26, 2024 ( GLOBE NEWSWIRE ) -- Krystal Biotech, Inc. ( the "Company" ) ( NASDAQ: KRYS ) , a commercial-stage biotechnology company, today announced that it will report its first quarter 2024 financial results on Monday, May 6, 2024, prior to the open of U.S. markets.
In Article Trend: Neutral
April 23, 2024 (13:35) / "Zacks Commentary" (by Zacks Equity Research)
Down -7.21% in 4 Weeks, Here's Why Krystal Biotech ( KRYS ) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Krystal Biotech (KRYS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
In Article Trend: Somewhat-Bullish
April 17, 2024 (20:32) / "Benzinga" (by Zacks)
Krystal Biotech is on the Move, Here's Why the Trend Could be Sustainable - Krystal Biotech ( NASDAQ:KRYS )
While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.
In Article Trend: Bullish
April 17, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
Krystal Biotech ( KRYS ) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
In Article Trend: Bullish
April 1, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
Recent Price Trend in Krystal Biotech ( KRYS ) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
In Article Trend: Bullish
March 31, 2024 (13:15) / "Motley Fool" (by Prosper Junior Bakiny)
1 Top Growth Stock to Buy and Hold Forever
This drugmaker looks unstoppable.
In Article Trend: Somewhat-Bullish
March 14, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
Krystal Biotech, Inc. ( KRYS ) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech, Inc. (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
In Article Trend: Bullish
March 13, 2024 (19:15) / "Benzinga" (by Benzinga Insights)
( KRYS ) - Analyzing Krystal Biotech's Short Interest - Krystal Biotech ( NASDAQ:KRYS )
Krystal Biotech's KRYS short percent of float has risen 21.27% since its last report. The company recently reported that it has 2.47 million shares sold short, which is 10.15% of all regular shares that are available for trading.
In Article Trend: Somewhat-Bullish
March 12, 2024 (21:00) / "Benzinga" (by Benzinga Insights)
$100 Invested In This Stock 5 Years Ago Would Be Worth $800 Today - Krystal Biotech ( NASDAQ:KRYS )
Krystal Biotech KRYS has outperformed the market over the past 5 years by 40.23% on an annualized basis producing an average annual return of 53.08%. Currently, Krystal Biotech has a market capitalization of $5.06 billion.
In Article Trend: Somewhat-Bullish
March 8, 2024 (17:20) / "Zacks Commentary" (by Zacks Equity Research)
Can Krystal Biotech, Inc. ( KRYS ) Run Higher on Rising Earnings Estimates?
Krystal Biotech, Inc. (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
In Article Trend: Bullish
March 8, 2024 (17:00) / "Zacks Commentary" (by Zacks Equity Research)
What Makes Krystal Biotech, Inc. ( KRYS ) a New Buy Stock
Krystal Biotech, Inc. (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
In Article Trend: Somewhat-Bullish
March 8, 2024 (17:00) / "Zacks Commentary" (by Zacks Equity Research)
Krystal Biotech, Inc. ( KRYS ) is a Great Momentum Stock: Should You Buy?
Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
In Article Trend: Somewhat-Bullish
March 5, 2024 (15:56) / "Benzinga" (by Avi Kapoor)
NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday - Dave ( NASDAQ:DAVE ) , NIO ( NYSE:NIO ) , Riskified ( NYSE:RSKD )
U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday. Shares of NIO Inc. NIO rose during Tuesday's session following upbeat quarterly results. NIO reported fourth-quarter revenue of 17.10 billion yuan ( $2.41 billion ) , up by 6.5% year-over-year and down by ...
In Article Trend: Somewhat-Bullish
March 4, 2024 (14:10) / "Forbes" (by Joshua Cohen)
Science Continues To Outpace Commercialization Of Cell And Gene Therapies
Biotechnology stocks are experiencing somewhat of a revival this year. It has even lifted some cell and gene therapy company share prices, though certainly not all of them. The continued lack of robust revenue for approved cell and gene therapies is a reminder that being innovative doesn't ...
In Article Trend: Somewhat-Bullish
March 1, 2024 (12:31) / "Motley Fool" (by Prosper Junior Bakiny)
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
It will take a lot, but this goal isn't out of reach for these stocks.
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
Fulcrum Therapeutics, Inc. (FULC)
Aptorum Group Limited (APM)
Illumina, Inc. (ILMN)
ACADIA Pharmaceuticals Inc. (ACAD)
Petros Pharmaceuticals, Inc. (PTPI)
Foghorn Therapeutics Inc. (FHTX)
Spruce Biosciences, Inc. (SPRB)
BioDelivery Sciences International, Inc. (BDSI)
Humana Inc. (HUM)
MediciNova, Inc. (MNOV)
This website uses cookies to ensure you get the best experience on our website